NAV

Phenoxypropazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Phenoxypropazine
DrugBank Accession Number
DB09251
Background

Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the hydrazine chemical class. It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.

Type
Small Molecule
Groups
Withdrawn
Structure
3D
Similar Structures
Weight
Average: 166.224
Monoisotopic: 166.110613079
Chemical Formula
C9H14N2O
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of depression.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Phenoxypropazine is combined with 1,2-Benzodiazepine.
AbaloparatidePhenoxypropazine may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Abciximab.
AcarbosePhenoxypropazine may increase the hypoglycemic activities of Acarbose.
AcebutololPhenoxypropazine may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Drazine

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkyl aryl ether / Alkylhydrazine / Aromatic homomonocyclic compound / Ether / Hydrazine derivative / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
8E92V52324
CAS number
3818-37-9
InChI Key
QNEXFJFTGQBXBJ-UHFFFAOYSA-N
InChI
InChI=1S/C9H14N2O/c1-8(11-10)7-12-9-5-3-2-4-6-9/h2-6,8,11H,7,10H2,1H3
IUPAC Name
(1-phenoxypropan-2-yl)hydrazine
SMILES
[H]N([H])N([H])C(C)COC1=CC=CC=C1

References

General References
  1. LEAHY MR, ROSE JT, PLOWMAN R: A preliminary study of phenoxypropazine in the treatment of depression. Am J Psychiatry. 1963 Apr;119:986-7. [Article]
  2. IMLAH NW: Preliminary report on phenoxypropazine. Am J Psychiatry. 1963 May;119:1091-2. [Article]
  3. ROSE JT, LEAHY MR, PLOWMAN R: A COMPARISON OF PHENOXYPROPAZINE AND AMYTRYPTILINE IN DEPRESSION. Am J Psychiatry. 1963 Oct;120:393-5. [Article]
PubChem Compound
71467
PubChem Substance
310265154
ChemSpider
64548
ChEBI
134799
ChEMBL
CHEMBL1909286
Wikipedia
Phenoxypropazine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.03 mg/mLALOGPS
logP1.37ALOGPS
logP1.25Chemaxon
logS-1.4ALOGPS
pKa (Strongest Basic)5.45Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area47.28 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity59.87 m3·mol-1Chemaxon
Polarizability18.67 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dj-9000000000-3d6f8a57b8b13de0b5cc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-f1b14f7517ebc214fb0a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fu-9000000000-b7032739a9ecdd7c7127
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-dfeb5512d5b15060afb9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-bc4dfd9e103e3b41ab8f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gdi-9000000000-9335928b558a46cb62d6
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-132.21179
predicted
DeepCCS 1.0 (2019)
[M+H]+134.60744
predicted
DeepCCS 1.0 (2019)
[M+Na]+140.51996
predicted
DeepCCS 1.0 (2019)

Drug created at October 24, 2015 04:12 / Updated at June 12, 2020 16:52